ImmediapressDragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors Di Redazione - 12 Novembre 2019 CondividiFacebook Twitter WhatsApp Linkedin Email Print Telegram